According to the data monitored by the "A-share green report" project, Zhejiang Starry Pharmaceutical Co.Ltd(603520) (603520. SH) holding subsidiary Zhejiang Taizhou Haishen Pharmaceutical Co., Ltd. has an annual output of 400 tons of iohexol and 200 tons of iodopanol, which has been approved in principle. The total investment of the project is 340 million yuan. The approval information was disclosed by relevant regulatory authorities on December 22, 2021.
The "A-share green report" project is jointly launched by the daily economic news and the well-known NGO Public Environmental Research Center (IPE) in the field of environmental protection, aiming to make the environmental information of listed companies more sunny and transparent. Based on the authoritative environmental regulatory data released by 31 provinces, municipalities and 337 prefecture level municipal governments, the project selects and monitors the environmental performance of listed companies and their subsidiaries (including branches, joint-stock companies and holding companies), makes professional data analysis and in-depth interpretation, intelligently writes daily, timely publishes the AI green report of listed companies, and launches the A-share green weekly report every week, Regularly and dynamically update the environmental risk list of listed companies.
The A-share green weekly report of the previous period (the 58th issue in total) shows that a total of 39 listed companies have recently exposed environmental risks, mainly in Beijing, Guangdong, Jiangsu and Zhejiang. Among them, 17 are state-owned controlled enterprises and 7 are enterprises with a market value of 100 billion. In addition to environmental risks, in the third week of December 2021, a total of 15 projects of A-share listed companies and their subsidiaries entered the publicity status of EIA approval.
According to the 2020 annual report, the main business of Zhejiang Starry Pharmaceutical Co.Ltd(603520) is pharmaceutical industry and other industries, accounting for 98.65% and 0.53% of revenue respectively.
(Daily Economic News)
